Selected article for: "acute develop and lung damage"

Author: Parra Gordo, M. L.; Weiland, G. Buitrago; García, M. Grau; Choperena, G. Arenaza
Title: Radiologic aspects of COVID-19 pneumonia: outcomes and thoracic complications
  • Cord-id: gw93rlzu
  • Document date: 2021_1_18
  • ID: gw93rlzu
    Snippet: Outcomes vary widely in patients with COVID-19. Whereas some patients have only mild symptoms of short duration, others develop severe disease that leads to acute respiratory distress syndrome requiring prolonged stays in intensive care units. Radiologically, the initial stage is characterized by viral pneumonia with mild expression. In some patients, however, the onset of the immune response results in acute lung damage with organizing pneumonia and diffuse alveolar damage. Moderate-severe dise
    Document: Outcomes vary widely in patients with COVID-19. Whereas some patients have only mild symptoms of short duration, others develop severe disease that leads to acute respiratory distress syndrome requiring prolonged stays in intensive care units. Radiologically, the initial stage is characterized by viral pneumonia with mild expression. In some patients, however, the onset of the immune response results in acute lung damage with organizing pneumonia and diffuse alveolar damage. Moderate-severe disease is associated with a high incidence of pulmonary embolisms, generally peripherally distributed and associated with endothelial damage, prolonged stays in bed, and coagulopathy. Other relatively common complications are spontaneous pneumothorax and pneumomediastinum due to the rupture of alveolar walls and barotrauma in mechanically ventilated patients. Superinfection, generally bacterial and less commonly fungal, is more common in patients with severe disease.

    Search related documents:
    Co phrase search for related documents
    • acute coronary syndrome and low molecular weight: 1, 2, 3, 4
    • acute coronary syndrome and low molecular weight heparin: 1, 2, 3, 4
    • acute coronary syndrome and lung damage: 1, 2
    • acute coronary syndrome and lung infection: 1, 2
    • acute coronary syndrome and lung involvement: 1, 2
    • acute coronary syndrome and lymphocyte count: 1, 2
    • acute coronary syndrome and magnetic resonance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute cytokine storm systemic inflammatory response and lung response: 1
    • acute damage and liver enzyme: 1, 2
    • acute damage and low molecular: 1, 2, 3, 4, 5
    • acute damage and low molecular weight: 1, 2, 3, 4
    • acute damage and low molecular weight heparin: 1, 2, 3
    • acute damage and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
    • acute damage and lung damage response: 1, 2, 3, 4, 5, 6
    • acute damage and lung heart: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute damage and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute damage and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute damage and lung involvement: 1, 2, 3, 4, 5, 6
    • acute damage and lung parenchyma: 1, 2, 3, 4, 5, 6, 7